AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10877732 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine, 0.5%, 15 mg (3 ml) injected intrathecally with torso elevated 30 degrees
Number of subjects: 40
Study 9165550 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose of tacrolimus
Number of subjects: 12
Study 9165550 — intervention group
Group type: COMPARATOR
Intervention: Evening dose of tacrolimus
Number of subjects: 12
Study 1375485 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus G‐CSF
Number of subjects: 0
Study 1375485 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 1375485 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells harvested after chemotherapy plus G‐CSF
Number of subjects: 0
Study 1375485 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment blood
Number of subjects: 0
Study 3910524 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (500 mg six hourly for seven days)
Number of subjects: 40
Study 3910524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg six hourly for seven days)
Number of subjects: 40
Study 30720338 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-and-night hybrid closed-loop system
Number of subjects: 24
Study 29703793 — intervention group
Group type: COMPARATOR
Intervention: MET 1000 mg BID
Number of subjects: 28
Study 29703793 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBI (MET 1000 mg BID + liraglutide 1.2 mg QD s.c.)
Number of subjects: 28
Study 27568804 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 0
Study 27568804 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 0
Study 25311606 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood food and service retail scale
Number of subjects: 174
Study 25311606 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood physical disorder scale
Number of subjects: 174
Study 23040114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower hemoglobin levels (≤ 11 g/dL)
Number of subjects: 1763
Study 23040114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >11-12 g/dL
Number of subjects: 1763
Study 23040114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >12-13 g/dL
Number of subjects: 1763
Study 23040114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >13-14 g/dL
Number of subjects: 1763
Study 23040114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >14-15 g/dL
Number of subjects: 1763
Study 23040114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >15 g/dL
Number of subjects: 1763
Study 19261825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 890
Study 19261825 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 890
Study 17583621 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified toddler formula (500 mL/day)
Number of subjects: 33
Study 17583621 — intervention group
Group type: COMPARATOR
Intervention: Unmodified cow's milk (500 mL/day)
Number of subjects: 33
Study 15241911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone application for 10 seconds
Number of subjects: 26
Study 15241911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone application for 20 seconds
Number of subjects: 26
Study 15241911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone application (10 or 20 seconds)
Number of subjects: 26
Study 12575622 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (SYNAGIS) - 5 monthly injections
Number of subjects: 1502
Study 12575622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1502
Study 9647273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate powder at a dose of 16 mg/day administered by a metered dose inhaler (Group A)
Number of subjects: 0
Study 9647273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aqueous solution at a dose of 80 mg/day administered by a nebulizer (Group N)
Number of subjects: 0
Study 9647273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aqueous solution (80 mg/day) combined with salbutamol (3 mg/day) administered by a nebulizer (Group C)
Number of subjects: 0
Study 7912950 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia (fentanyl and droperidol)
Number of subjects: 75
Study 7912950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC of halothane with 66% nitrous oxide in oxygen
Number of subjects: 75
Study 7912950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC of isoflurane with 66% nitrous oxide in oxygen
Number of subjects: 75
Study 7912950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC of enflurane with 66% nitrous oxide in oxygen
Number of subjects: 75
Study 7912950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC of sevoflurane with 66% nitrous oxide in oxygen
Number of subjects: 75
Study 2480798 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-23 treatment
Number of subjects: 19
Study 2480798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 1103207 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 12
Study 1103207 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.035 mg/kg)
Number of subjects: 12
Study 1103207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31335730 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhardness testing in the anterior region of tibial diaphysis
Number of subjects: 3
Study 31335730 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhardness testing in the medial region of tibial diaphysis
Number of subjects: 3
Study 31335730 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhardness testing in the posterior region of tibial diaphysis
Number of subjects: 3
Study 31335730 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhardness testing in the lateral region of tibial diaphysis
Number of subjects: 3
Study 28789789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue and depression
Number of subjects: 367
Study 28789789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue, sleep and pain beliefs/attitudes
Number of subjects: 367
Study 28789789 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 367
Study 28789789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 367
Study 26142914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb lymphedema (LLL) group
Number of subjects: 53
Study 26142914 — intervention group
Group type: COMPARATOR
Intervention: Control group (without LLL)
Number of subjects: 53
Study 23291729 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose influenza vaccine (30 μg/strain)
Number of subjects: 28
Study 23291729 — intervention group
Group type: COMPARATOR
Intervention: Standard dose influenza vaccine (15 μg/strain)
Number of subjects: 28
Study 21885537 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage in addition to guidelines and exercise therapy
Number of subjects: 160
Study 21885537 — intervention group
Group type: COMPARATOR
Intervention: Control group (guidelines and exercise therapy without manual lymph drainage)
Number of subjects: 160
Study 16675716 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/m² of IV methotrexate over 24 hr (Group 1)
Number of subjects: 32
Study 16675716 — intervention group
Group type: COMPARATOR
Intervention: 2 g/m² of IV methotrexate over 4 hr (Group 2)
Number of subjects: 32
Study 15723939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of m‐THPC 6 days before direct endoscopic PDT with 80 to 100 J of light for adults and 60 to 80 J for children
Number of subjects: 23
Study 15723939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 12477995 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 36
Study 12477995 — intervention group
Group type: COMPARATOR
Intervention: MVAC + GM‐CSF (molgramostim)
Number of subjects: 36
Study 9605777 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 97
Study 9605777 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study 7701450 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 2 mg (S2)
Number of subjects: 8
Study 7701450 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg (S4)
Number of subjects: 8
Study 7701450 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 8 mg (S8)
Number of subjects: 8
Study 7701450 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg (PR)
Number of subjects: 8
Study 7701450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 2634111 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study 333188 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 300 mg every 6 hours for up to 5 days or until 1 day after chest tube removal
Number of subjects: 75
Study 333188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31840263 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused treatment for childhood depression (FFT-CD)
Number of subjects: 134
Study 31840263 — intervention group
Group type: COMPARATOR
Intervention: Individual supportive psychotherapy (IP)
Number of subjects: 134
Study 31274720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless TKA
Number of subjects: 141
Study 31274720 — intervention group
Group type: COMPARATOR
Intervention: Cemented TKA
Number of subjects: 141
Study 28711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated RR reports for renal scarring
Number of subjects: 607
Study 28711547 — intervention group
Group type: COMPARATOR
Intervention: ALR reports for renal scarring
Number of subjects: 607
Study 28711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated RR reports for acute pyelonephritis
Number of subjects: 607
Study 28711547 — intervention group
Group type: COMPARATOR
Intervention: ALR reports for acute pyelonephritis
Number of subjects: 607
Study 28711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement rate for DMSA scan reports
Number of subjects: 607
Study 28711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on renal scarring presence
Number of subjects: 607
Study 28711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Two of three agreement on renal scarring
Number of subjects: 607
Study 28711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on pyelonephritis presence
Number of subjects: 607
Study 28711547 — intervention group
Group type: EXPERIMENTAL
Intervention: Two of three agreement on pyelonephritis
Number of subjects: 607
Study 24690589 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg per day)
Number of subjects: 17
Study 24690589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (malt-dextrin)
Number of subjects: 17
Study 24083730 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW HBV education intervention
Number of subjects: 87
Study 21457064 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical moist heat wrap
Number of subjects: 120
Study 21457064 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermaCare heat wraps
Number of subjects: 120
Study 21457064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocollator heat wraps
Number of subjects: 120
Study 21457064 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist heat
Number of subjects: 120
Study 21457064 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 120
Study 21457064 — intervention group
Group type: COMPARATOR
Intervention: Younger group
Number of subjects: 120
Study 21457064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 120
Study 18021751 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic information presentation
Number of subjects: 0
Study 18021751 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual information presentation
Number of subjects: 0
Study 18021751 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct error feedback (haptic or visual)
Number of subjects: 0
Study 18021751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perception of haptic parallelity
Number of subjects: 0
Study 16808682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA)
Number of subjects: 40
Study 16808682 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 40
Study 15346754 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of sinus membrane perforation with freeze-dried human lamellar bone sheet (Lambone)
Number of subjects: 63
Study 15346754 — intervention group
Group type: COMPARATOR
Intervention: No repair of sinus membrane perforation (control group)
Number of subjects: 63
Study 15046713 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents tested with chemotherapy
Number of subjects: 0
Study 15046713 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of previously studied chemotherapeutic agents
Number of subjects: 0
Study 9661327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (nurse-led, 8-week program)
Number of subjects: 222
Study 9661327 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 222
Study 7661266 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine
Number of subjects: 0
Study 7661266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 0
Study 7661266 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0
Study 2526101 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (600 mg daily)
Number of subjects: 16
Study 2526101 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (150 mg daily)
Number of subjects: 16
Study 2526101 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective drug preference
Number of subjects: 16
Study 2526101 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 16
Study 334083 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cloxacillin therapy
Number of subjects: 0
Study 334083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31390835 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR)
Number of subjects: 1032
Study 31390835 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 1032
Study 31390835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1032
Study 31390835 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Intakes (RIs)
Number of subjects: 1032
Study 31390835 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning symbols
Number of subjects: 1032
Study 31390835 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 1032
Study 28244897 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting
Number of subjects: 138
Study 28244897 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication (telmisartan)
Number of subjects: 138
Study 26870806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model containing 8 genes plus MSKCC clinical risk factors
Number of subjects: 324
Study 26870806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model containing 8 genes without MSKCC risk factors
Number of subjects: 324
Study 26870806 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk factors alone
Number of subjects: 324
Study 23721363 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (25 mg)
Number of subjects: 2271
Study 23721363 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with valsartan (320 mg) and hydrochlorothiazide (25 mg)
Number of subjects: 2271
Study 23721363 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with amlodipine (10 mg) and valsartan (320 mg)
Number of subjects: 2271
Study 23721363 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with amlodipine (10 mg) and hydrochlorothiazide (25 mg)
Number of subjects: 2271
Study 21823286 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming‐promotion acupuncture (Group A)
Number of subjects: 64
Study 21823286 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (Group B)
Number of subjects: 64
Study 19786244 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical thrombectomy
Number of subjects: 0
Study 19786244 — intervention group
Group type: COMPARATOR
Intervention: Endovascular intervention
Number of subjects: 0
Study 19786244 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of autogenous arteriovenous fistulae
Number of subjects: 0
Study 19786244 — intervention group
Group type: COMPARATOR
Intervention: Endovascular intervention for autogenous arteriovenous fistulae
Number of subjects: 0
Study 15274674 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 119
Study 15274674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 11583718 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg daily) for 3 months
Number of subjects: 36
Study 11583718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 9181656 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 843
Study 9181656 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 843
Study 8215814 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (mean maximum daily dose, 143 mg)
Number of subjects: 230
Study 8215814 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (255 mg)
Number of subjects: 230
Study 8215814 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (26 mg)
Number of subjects: 230
Study 8215814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 8215814 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (Imipramine and Trazodone)
Number of subjects: 230
Study 8215814 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 230
Study 3651278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.2 g kg‐1
Number of subjects: 8
Study 3651278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.4 g kg‐1
Number of subjects: 8
Study 3651278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g kg‐1
Number of subjects: 8
Study 3651278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31800679 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 80
Study 31800679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 31800679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parecoxib and dexmedetomidine
Number of subjects: 80
Study 31800679 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29069370 — intervention group
Group type: EXPERIMENTAL
Intervention: idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w
Number of subjects: 1284
Study 29069370 — intervention group
Group type: COMPARATOR
Intervention: Standard epirubicin/cyclophosphamide followed by paclitaxel (EC→P) q3w
Number of subjects: 1284
Study 27364568 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) given alongside measles-rubella and yellow fever vaccines
Number of subjects: 1504
Study 27364568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional intradermal doses of IPV
Number of subjects: 1504
Study 27364568 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-rubella and yellow fever vaccines co-administered with IPV
Number of subjects: 1504
Study 27364568 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Number of subjects: 1504
Study 27364568 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliovirus vaccine
Number of subjects: 1504
Study 24203058 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese men
Number of subjects: 20
Study 22250189 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carmustine following intravenous O6-benzylguanine
Number of subjects: 21
Study 22250189 — intervention group
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Number of subjects: 21
Study 22250189 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carmustine
Number of subjects: 21
Study 19291787 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 1050
Study 19291787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 1050
Study 19291787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Interferon and Control)
Number of subjects: 1050
Study 19291787 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a decrease in steatosis
Number of subjects: 1050
Study 17574311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized formulation of RTS,S/AS02A
Number of subjects: 34
Study 17574311 — intervention group
Group type: COMPARATOR
Intervention: Liquid formulation of RTS,S/AS02A
Number of subjects: 34
Study 15614114 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin (2.4 MU intramuscularly)
Number of subjects: 952
Study 15614114 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g orally)
Number of subjects: 952
Study 15614114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual treatment (azithromycin and benzathine penicillin)
Number of subjects: 952
Study 15614114 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial titers < or =1:2 (all treatments)
Number of subjects: 952
Study 15614114 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial titers > or =1:4
Number of subjects: 952